-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca camizestrant combo wins EU CHMP backing for advanced ER-positive breast cancer

PUBT·05/22/2026 11:22:24
Listen to the news
AstraZeneca camizestrant combo wins EU CHMP backing for advanced ER-positive breast cancer
  • AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor won a positive CHMP opinion for EU approval in first-line ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
  • The SERENA-6 Phase III trial showed a 56% cut in the risk of disease progression or death versus an aromatase inhibitor regimen, with median PFS of 16.0 months versus 9.2 months.
  • Regulatory filings in this setting remain under review in the US, Japan, and other markets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on May 22, 2026, and is solely responsible for the information contained therein.